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ABSTRACT
Background: Uteroglobin-related protein 1 (UGRP1) is a secretory protein expressed in the airways and is
speculated to have anti-inflammatory activity. In the mouse, its gene expression is down-regulated by inter-
leukin (IL)-5 and -9, and up-regulated by IL-10. However, the precise role of UGRP1 in human inflammatory air-
way diseases such as asthma has not been clarified. The objectives of this study were to establish an ELISA
system to quantify UGRP1 protein, and to examine whether plasma UGRP1 levels are associated with the G-
112A polymorphism, asthma susceptibility, and its severity.
Methods: 152 asthma patients and 103 normal controls were involved in this study. Mice were immunized
with recombinant UGRP1 and hybridoma cell lines were established. A sandwich ELISA system was estab-
lished by using two monoclonal antibodies recognizing different epitopes. Plasma UGRP1 levels were meas-
ured with the ELISA system and the G-112A allele was detected by using real-time PCR.
Results: An ELISA system was established that allowed determination of UGRP1 levels within the range of
9.6―1250 pgml. The mean plasma UGRP1 levels for subjects with -112A allele were significantly lower than
those without it (p = 0.025). Although there was no significant difference in the plasma UGRP1 levels between
asthma patients and controls (p = 0.13), severe asthma patients without oral corticosteroid had significantly
lower plasma UGRP1 levels compared to mild- or moderate- asthma patients and controls (p = 0.004, 0.03 and
0.003, respectively).
Conclusions: The ELISA system for quantifing UGRP1 protein was established, and plasma UGRP1 levels
were associated with the G-112A UGRP1 gene promoter polymorphism and the severity of asthma.
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INTRODUCTION
The uteroglobin-related protein 1 (UGRP1) gene, offi-
cially named secretoglobin 3A2 (SCGB3A2) encodes
a homodimeric secretory protein of 10 kDa.1 It was
originally identified as a downstream target gene for
the homeodomain transcription factor, thyroid-
specific enhancer-binding protein (TEBP), also
called thyroid transcription factor 1 (TTF1) or NKX
2.1.2 TEBP regulates the expression of thyroid- and
lung-specific genes, the latter of which includes sur-
factant proteins A, B, and C, and Clara cell secretory
protein (CCSP).1,3-6 Mice homozygous for the dis-
rupted gene for Tebp were born dead and lacked
lung parenchyma, demonstrating that TEBP plays
an essential role in lung development.7 In murine
lung, UGRP1 is expressed mainly in the airway epi-
thelial cells and is an early molecular marker for
Clara cells.8 The spatial distribution of UGRP1 is simi-
lar between humans and mice although in humans
the expression is primarily found in serous-like cells
of bronchi and associated glands.8 These findings
suggest that UGRP1 may play a significant physi-
ological role in the lung. However, little is known
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about the function of UGRP1.
The amino acid sequence of human UGRP1 has
25% identity to human CCSP (SCGB1A1), a prototypi-
cal member of the SCGB gene super-family, that is
believed to function as an anti-inflammatory protein.2
The expression pattern of UGRP1 is similar to that of
CCSP although UGRP1 expression is found in the
epithelial cells of the trachea where CCSP is not ex-
pressed.2 The CCSP family (SCGB1A) proteins are
characterized by the presence of two conserved cys-
teine residues at the N- and C-terminal regions of
polypeptides separated by a lysine that are required
to form a dimmer.9 The area containing the con-
served lysine residue is called antiflammin.9 The anti-
flammin domain exhibits potent anti-inflammatory
and immunomodulatory activities and appears to be
responsible for the PLA2-inhibitory activity of
CCSP.9,10 The amino acid sequence similarities be-
tween UGRP1 and the CCSP family proteins are sig-
nificant in the areas of the signal peptide and anti-
flammin.2 These findings suggest that UGRP1 may
also have an anti-inflammatory function.
Recently, it was reported that allergen-induced in-
flammation in allergen-sensitized mice was associated
with a reduction in UGRP1 mRNA expression in lung
as compared with naïve animals, and the expression
returned to normal with dexamethasone treatment.2
Further, the possible involvement of interleukin (IL)-
5 and -9 in the decreased airway UGRP1 expression
in allergic airway inflammation was demon-
strated.11,12 On the other hand, IL-10, known as an
anti-inflammatory cytokine, induced Ugrp1 gene ex-
pression in lung epithelial cells, suggesting that
UGRP1 might be a target for the anti-inflammatory
activities of IL-10.13
The human UGRP1 gene is located on chromo-
some 5q31―32, the area containing one or more
genes that may potentially play a role in airway in-
flammation associated with atopic asthma. These
genes include a number of proinflammatory cytoki-
nes such as IL-3, -4, -5, -9, and -13.14-18 We previously
reported the presence of a G to A polymorphism at -
112 bp in the human UGRP1 gene promoter and that
the -112A allele is responsible for a 24% reduction in
the promoter activity as compared to the wild-type
-112G allele.19 This polymorphism exhibited a signifi-
cant association with asthma phenotype in an adult
Japanese population.19
In the present study, we established an ELISA as-
say to measure the concentration of human UGRP1
in plasma. Using this ELISA system, we successfully
demonstrated an association of UGRP1 levels to the
G-112A polymorphism and the severity of asthma.
METHODS
SUBJECTS
A total of 255 Japanese subjects, 152 asthma patients
and 103 controls, were enrolled in this study. Sub-
jects with bronchial asthma were recruited from the
outpatient clinic at the Fukushima Medical University
Hospital according to the following criteria: First, the
presence of at least two of the following symptoms
was examined: recurrent cough, wheezing or dysp-
nea. Second, we examined for increased airway re-
sponsiveness to methacholine or the presence of re-
versible airflow limitation; the latter refers to 15% vari-
ability in the forced expiratory volume in 1 second
(FEV1), or in the peak expiratory flow rate with or
without an inhaled short-acting β2-agonist. The third
criterion was the absence of any other pulmonary dis-
eases. Control subjects were normal volunteers who
had no symptoms, or past history of asthma, or other
airway or allergic diseases. All asthma patients had
been treated according to the Japanese Asthma Pre-
vention and Management Guideline20 and were at a
clinically stable phase. Lung function, serum nonspe-
cific IgE, and antigen-specific IgE for 10 common in-
halant antigens including house-dust mites, molds,
pollens, and animal dander (cat and dog) were exam-
ined in both asthma patients and controls. Concentra-
tions of antigen-specific IgE of more than 0.69 UAml
were considered as positive. Subjects were character-
ized as “atopic” if they had at least one positive
antigen-specific IgE or a nonspecific IgE level of 250
IUml or greater. The severity of asthma was classi-
fied into mild, moderate and severe, according to the
Global Initiative for Asthma (GINA) guideline.21 DNA
was extracted from peripheral blood cells. All of the
participants gave informed consent and the study was
approved by the ethical committee of the Fukushima
Medical University.
EXPRESSION AND PURIFICATION OF HUMAN
UGRP1 PROTEIN
Expression of recombinant human UGRP1 (hUGRP1)
was performed using the pET Expression System
(Novagen, EMD Biosciences, Dermstdt, Germany).
A cDNA encoding UGRP1 mature sequence was sub-
cloned in-frame into pET32a (+), which was trans-
formed into E. coli OrigamiDE3. A scaled-up culture
was performed in LB medium containing 0.1 mgml
ampicillin and hUGRP1 expression was induced by
the addition of 1 mM IPTG. The cultured medium
was centrifuged at 8,000 rpm for 15 minutes and pel-
lets were suspended in binding buffer (20 mM Tris-
HCl buffer, pH 8.0 containing 0.5 M NaCl and 5 mM
imidazole). The suspension was sonicated and centri-
fuged at 18,000 rpm for 15 minutes, and supernatants
were collected. hUGRP1 in the supernatants was pu-
rified with a Ni2+-charged HiTrap Chelating HP col-
umn equipped with ÄKTAprime purification system
(Amersham Biosciences, Buckinghamshire, UK).
Briefly, samples were loaded onto the column equili-
brated with binding buffer. The column was washed
with the binding buffer and elution was carried out
with a linear imidazole gradient from 5 to 500 mM.
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Fractions containing recombinant protein were col-
lected and dialyzed against 20 mM Tris-HCl buffer,
pH 7.4, resulting in purified hUGRP1. The N-terminal
His-tag of hUGRP1 was then removed by cleavage
with thrombin using the Thrombin Cleavage Capture
Kit (Novagen). The cleaved His-tag peptide was re-
moved by incubation with Ni-NTA agarose (Qiagen,
Hilden, Germany). The hUGRP1 (with His-tag) and
mature UGRP1 (without His-tag) were used as a stan-
dard for ELISA and a protein antigen for immuniza-
tion, respectively.
MONOCLONAL ANTIBODIES
Monoclonal antibodies against hUGRP1 were ob-
tained by immunizing BALBc mice with mature
hUGRP1 prepared as above. Briefly, spleen cells from
immunized mice were fused with myeloma-cells
(SP2) by using polyethylene glycol to produce hy-
bridoma cell lines. Five hybridoma-cell lines that
survived the hypoxanthine-aminopterin-thymidine
(HAT) selection were chosen for further studies.
Each hybridoma-cell line was confirmed for its appro-
priate antibody titer, and the class of monoclonal anti-
body was determined as IgG1K for all five hybri-
doma-cell lines. Each of the cloned hybridoma-cell
lines were grown as tumors in mouse abdominal cavi-
ties. Each monoclonal antibody was collected from
their ascites fluid and purified with a protein G col-
umn. Specificity of five antibodies was confirmed by
examining specific findings to hUGPR1 by Western
blotting. Two monoclonal antibodies (MoAb 4 G10
and 5B1), recognizing different epitopes of hUGRP1,
were selected for the sandwich ELISA system. MoAb
4G10 was prepared as a capture antibody. MoAb 5B1
was used as a detection antibody after labeling with
horseradish peroxidase using a Peroxidase Labeling
Kit (Roche, Grenzacherstrasse, Switzerland) accord-
ing to the manufacturer’s instruction. The protocols
to produce monoclonal antibodies were approved by
the Institutional Animal Care and Use Committee.
QUANTITATION OF UGRP1
UGRP1 concentrations were measured with ELISA.
Briefly, SUMIRON Multi Well Plates for ELISA (Su-
mitomo Bakelite Co., Ltd, Tokyo, Japan) were coated
overnight at 4℃ with MoAb 4G10 at a concentration
of 1 μgml in Tris-buffered saline (TBS), pH 7.4. Af-
ter unbound antibody was removed, the plate was
blocked with 300 μl of 1% bovine serum albumin in
TBS (BSA-TBS). Standards or samples (100 μl) were
added and allowed to react with the coated antibody
at 37℃ for 60 minutes. Unbound antigen was re-
moved, and then 100 μl of horseradish peroxidase-
conjugated MoAb 5B1 diluted 1 in 500 in BSA-TBS
was added, followed by incubation at 37℃ for 60 min-
utes. After repeating a wash with 0.05% Tween 20 in
TBS, 100 μl substrate solution (prepared according
to the manufacturer’s instruction) was added to each
well. Enzyme activity was measured at the absor-
bance of 450 nm after terminating the reaction by the
addition of phosphoric acid (1M, 100 μl). A linear
standard curve was obtained between 9.6 and 1250
pgml of UGRP1. All assays were performed in dupli-
cate.
GENOTYPING
For each individual, the -112GA polymorphism in
the human UGRP1 gene promoter was determined
by real-time polymerase chain reactions (PCR). Alle-
lic discrimination assays were performed by a Taq-
man 7000 platform (Applied Biosystems, USA) ac-
cording to the manufacturer’s instruction. Briefly, the
PCR reaction contained 20 ng genomic DNA, 2.5 μL
Taqman master mix and 0.125 μL of 40X assay mix
which contains primers (forward; 5’ GCT GTA CTG
TAG AGC TTT GTT TCT CA 3’, reverse 5’ CCC CAC
CAA AGA AAG GGA TAA ATG T 3’) and probes
(wild type; VIC-CAA ATT GTT TGG TGA GAA A,
mutant type; FAM-TCC AAA TTG TTT AGT GAG
AAA). PCR was performed using 96 well plates in a
real-time PCR system (ABI PRISM 7000) with reac-
tion conditions of 95℃ for 10 minutes followed by 40
cycles of 92℃ for 15 seconds and 60℃ for 1 minute.
STATISTICAL ANALYSIS
Genotype distributions were analyzed by using the
SNP Analyze software (Dynacom, Kanagawa, Japan).
Statistical analyses were performed with SPSS II for
Windows. Values for UGRP1 and nonspecific IgE
were log transformed for statistical analysis, since
these values were log normally distributed in the
population. The Mann-Whitney U-test was used to
compare unpaired sets of data. The Chi square test
was used to analyze the relationship between the ex-
istence of the -112A allele and asthma status. One-
way analysis of variance test was used to analyze the
relationship between plasma UGRP1 levels and the
severity of asthma. Correlations were examined by
using Spearman rank analysis. The level of critical
significance was assigned at p values less than 0.05.
RESULTS
CHARACTERISTICS OF SUBJECTS
The numbers of control subjects and asthma patients
enrolled in this study were 103 and 152, respectively
(Table 1). There were significant differences between
the cases and control group with respect to age and
malefemale ratio. Asthma patients exhibited signifi-
cantly higher total serum IgE levels and atopicnon-
atopic ratio, and reduced pulmonary functions as
compared with the control group. Within asthma pa-
tients, no significant differences were found in these
parameters among mild, moderate and severe asthma
patients (p = 0.167).
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Fig. 1 The standard curve (log-log fit) for measuring 
UGRP1 levels. UGRP1 concentration can be accurately de-
termined between 9.6―1250 pg/ml.
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Table 1 Characteristics of the subjects
Asthma (n＝141)
Control (n＝103)
TotalSevere (n＝19)Moderate (n＝87)Mild (n＝35)
(43.7―48.2)45.9(37.7―49.2)43.5(44.2―50.4)47.3(40.0―47.8)43.9(29.1―31.9)＊30.5Age (y)
(45.4%)64/77(36.8%)7/12(47.1%)41/46(45.7%)16/19(60.2%)†62/41Sex, M/F
(male%)
(163.3―268.5)209.4(57.8―435.2)158.6(159.1―291.1)215.2(146.6―355.3)228.2(55.2―92.5)＊71.5Total IgE
(UA/ml)
(77.3%)109/32(63.2%)12/7(77.0%)67/20(85.7%)30/5(24.3%)＊25/78A/N
(Atopic%)
(2.31―2.58)2.45(2.08―2.83)2.46(2.19―2.56)2.38(2.37―2.85)2.61(2.72―3.39)＊3.05FEV1 (L)
(70.6―75.1)72.8(68.0―82.6)75.3(68.0―74.1)71.1(72.4―79.2)75.8(83.5―88.8)＊86.1FEV1% (%)
Data are expressed as geometric means and 95%CIs. Total IgE: total immunoglobulin E. M/F: male/female. A/N: atopic/non-atopic. 
FEV1: forced expiratory volume in 1 second. FEV1%: percentage of FEV1 in forced vital capacity. ＊p＜0.01 and †p＜0.05 compared with 
asthma patients.
QUANTIFICATION OF PLASMA UGRP1 LEVELS
The standard curve (log-log fit) for UGRP1 demon-
strated good linearity within 9.6―1250 pgml of
UGRP1 (r = 0.99), suggesting that UGRP1 levels can
be estimated within this range (Fig. 1). In only one
asthmatic subject, the level was over 1250 pgml; this
sample was diluted in assay buffer and re-measured.
Age and sex distributions did not affect plasma
UGRP1 levels (data not shown). There was no signifi-
cant correlation between nonspecific IgE and plasma
UGRP1 levels (p = 0.37), and no significant difference
in plasma UGRP1 levels between atopic and non-
atopic subjects (p = 0.88).
UGRP1 PROMOTER G-112A POLYMORPHISM,
ASTHMA PHENOTYPE AND PLASMA UGRP1
LEVELS
The frequencies of G-112A polymorphism were deter-
mined in control and asthmatic subjects (Table 2).
These genotype distributions were confirmed to fit to
Hardy-Weinberg distribution. Thirty-seven out of 103
normal control subjects (35.9%) had the -112A allele,
while 69 of 152 asthmatic subjects (44.3%) had the
-112A allele, suggesting a weak trend of a more fre-
quent presence of the -112A allele in asthma patients
as compared with control subjects although no statis-
tical significance was obtained. When asthma patients
were classified by the severity of their asthma, the
-112A allele was more frequently found in severe
asthma patients; although there was no statistically
significant difference.
When plasma UGRP1 levels were examined, those
having at least one -112A allele (GA or AA geno-
type) had a mean plasma UGRP1 level of 70.6+−6.8
(SE) pgml that was significantly lower than that of
wild-type subjects (GG genotype) (123.0+−18.0 pg
ml, p = 0.007). Significantly reduced plasma UGRP1
levels were also found for healthy control subjects
with A-allele (GA or GG genotype, 65.5+−9.6 pg
ml) as compared with those without A-allele (GG
genotype, 128.7+−24.7 pgml ) (p = 0.02)(Fig. 2).
ASTHMA PHENOTYPE AND PLASMA UGRP1
LEVELS
The average plasma UGRP1 level was 98.0+−14.7
(SE) pgml in asthma patients, and 106.0+−16.4 pg
ml in control subjects. Although asthma patients had
lower plasma UGRP1 levels as compared to controls,
the difference was not statistically significant
(p = 0.12, Fig. 3). Among asthma patients, the aver-
age plasma UGRP1 levels decreased in the order of
asthma severity; 112.7+−21.3 pgml, 106.0+−23.9
pgml and 57.6+−10.8 pgml for mild, moderate and
severe asthma patients, respectively, and severe
asthma patients tended to have lower plasma UGRP1
(p = 0.06). However, 11 of 19 severe asthma patients
were treated with systemic corticosteroids that have
been known to increase UGRP1 expression. For this
reason, this group was divided into two groups, sub-
jects treated with or without oral corticosteroid (OS).
Mean plasma UGRP1 levels for severe asthma pa-
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Fig. 2 Comparison of plasma UGRP1 levels between sub-
jects with (G/A or A/A) and without (G/G) -112A alele. The 
results for control subjects are shown. The total number of 
subjects with -112A alele was 37 and those without A alele 
was 66. Data are means ＋ /－ SE. ＊ p＝ 0.02 compared 
to control.
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Fig. 3 Comparison of plasma UGRP1 levels between con
trol and asthma patients. Data are means ＋ /－ SE. There 
was no statisticaly significant diference.
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Table 2 Distribution of UGRP1 G-112A genotype in asthmatic patients and controls
Asthma
Control
TotalSevereModerateMild
Genotype
(53.9%)76(36.8%)7(56.3%)49(57.1%)20(64.1%)66G/G
(46.1%)65(63.2%)12(43.7%)38(42.9%)15(35.9%)37G/A or A/A
 27.3 39.5 25.3 25.7 20.4A alele frequency (%)
(100%)141(100%)19(100%)87(100%)35(100%)103Total subjects
There was no significant diference between each group.
tients with- and without-OS were 92.0+−25.3 pgml
and 37.7+−5.7 pgml, and subjects with OS had sig-
nificantly higher plasma UGPR1 levels compared to
those without it (p = 0.013). In addition, as shown in
Figure 4, severe asthma patients without OS had sig-
nificantly lower plasma UGRP1 levels compared to
controls (p = 0.003) and mild and moderate asthma
patients (p = 0.004 and 0.03, respectively).
DISCUSSION
In this study, we established a sandwich ELISA sys-
tem to measure human UGRP1 protein concentra-
tions using two monoclonal antibodies produced
against human UGRP1. Plasma UGRP1 levels could
be determined by this ELISA system within the range
of 9.6―1250 pgml. Since in humans, expression of
UGRP1 is restricted to the airways, plasma UGRP1 is
likely to be derived from the respiratory tracts.2
By using this ELISA system, we demonstrated that
plasma UGRP1 levels are affected by the G-112A poly-
morphism of the UGRP1 gene promoter. We previ-
ously reported the functional significance of the G-
112A polymorphism in the promoter of UGRP1
gene.19 By luciferase reporter assays, a 24% reduction
of the promoter activity was observed for the -112A al-
lele as compared with the -112 G allele. Electropho-
retic mobility shift analysis revealed that this was due
to decreased affinity of a particular nuclear protein to
the -112A binding site.19 In the present study, the
mean plasma UGRP1 levels for subjects having at
least one -112A allele had 43% lower plasma UGRP1
levels than those having -112 G allele (70.6 and 123.0
pgml, respectively, p = 0.007). Previously, we also
demonstrated that the G-112A polymorphism of the
UGRP1 gene promoter is associated with asthma phe-
notypes.19 Later, two groups failed to find the same
association in populations of childhood asthma.22
This study was not designed to determine the asso-
ciation between asthma phenotype and genotype,
meaning that the number of subjects in this study
was not large enough to analyze this relation. In spite
of such a small subject number, the trend was similar
to the previous study in that subjects with the -112A
allele were more likely to have asthma than those
without (Table 2).
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Fig. 4 Comparison of plasma UGRP1 levels among 
healthy control and mild-severe asthmatic with or without 
oral corticosteroid (OS). Data are means ＋ /－ SE. ＊＊p＜
0.05  compared  to  control,  mild,  and  moderate  asthma. 
†p＝0.013 compared to severe asthma with OS.
Control
mild moderate severe
Asthma
U
G
R
P
1 
(p
g/
m
l)
0
50
100
150
†
＊＊
os(－) os(＋)
The most important finding in the present study is
that a significant association was observed between
plasma UGRP1 levels and the severity of asthma
when the subjects with severe asthma were grouped
according to oral corticosteroid use. Subjects treated
with oral corticosteroid had significantly higher
plasma UGRP1 levels. This phenomenon has already
been demonstrated in the mouse asthma model.2 The
reduced plasma UGRP1 levels in severe asthma pa-
tients without oral corticosteroid could be due to ge-
netic or acquired mechanisms. This study demon-
strated that the UGRP1 gene promoter polymor-
phism affects plasma UGRP1 levels and that the
-112A allele is more likely found in asthma patients
especially in severe asthma patients, although there
was no statistical significance. This suggests the pos-
sibility that the G-112A genotype could be an inde-
pendent determinant of plasma UGRP1 levels and
that UGRP1 might be one of the genetic determi-
nants of asthma severity.
Currently, only limited information is available for
the functional role of UGRP1 in lung. However, its
similarity to CCSP, especially in the antiflammin do-
main that exhibits major anti-inflammatory and immu-
nomodulatory activities, suggests a possible anti-
inflammatory function for UGRP1. In addition, the
suppression of allergic airway inflammation by an
over-expression of UGRP1 in the airways has been re-
ported in mice.23 A recent study also demonstrated
that the anti-inflammatory effect of IL-10 may be me-
diated by UGRP1.13 In general, IL-10 is associated
with resolution of the inflammatory response proc-
ess24 and is known to block allergic inflammation in
animal models.25,26 IL-10 is up-regulated during acute
exacerbation of asthma induced by viral infection, es-
pecially in its recovery phase.24,27-29 If the reduction
of UGRP1 levels is related to the G-112A UGRP1 pro-
moter polymorphism, the anti-inflammatory action of
IL-10 could be reduced in individuals with the -112A
allele. A defect in such anti-inflammatory functions in
the asthmatic airways might be related to the severity
of asthma.
Another possible mechanism for reduced plasma
UGRP1 levels in severe asthma is decreased UGRP1
production by remodeling of the small airways. In hu-
man airways, the major source of UGRP1 is non-
ciliated cells (such as Clara cells), in common with
CCSP.8 A decreased number of CCSP positive cells in
asthmatic airways have been also demonstrated.30
Further in asthma patients, a significant decrease of
CCSP was reported both in their bronchoalveolar lav-
age fluid31 and serum32 compared to control subjects.
Asthmatic patients with a long duration of the disease
(>=10 years) had significantly lower serum CCSP
levels than those with a short duration of the disease
(<10 years), which may reflect decreased production
of CCSP caused by remodeling of the small airways
in asthma.32 Since UGRP1 is also expressed mainly in
non-ciliated cells (such as Clara cells), a similar
mechanism could be estimated for UGRP1.8
In our previous study with a mouse model of aller-
gic airway inflammation, the expression of UGRP1
mRNA in lungs was reduced by antigen inhalation
and recovered by dexamethasone treatment.2 In addi-
tion, recent studies demonstrated that IL-5 and -9 re-
duce UGRP1 expression while IL-10 increases
UGRP1 expression in mouse airways.11-13 These re-
sults suggest a possible reduction of UGRP1 expres-
sion in human asthmatic airways because IL-5 and -9
are known to be elevated in asthmatic airways.33 In
this study, the mean plasma UGRP1 levels for asthma
patients were close to that of controls (98.0 pgml
and 106 pgml, respectively). One possible explana-
tion for this discrepancy is that plasma UGRP1 levels
are associated with asthma severity independent of
asthma phenotype as shown in Figure 4, in which
plasma UGRP1 levels of mild asthma patients are
similar or slightly higher than those of controls.
Another explanation for this discrepancy might be
due to a difference in mechanisms of asthma between
humans and mice. Th2 dominated immune responses
have been recognized to cause allergic diseases in-
cluding asthma in mice,34,35 whereas in humans the
pattern of T-cell immunity is thought to be more het-
erogenous.36 Some examples include production of
IL-10, which is a Th2 marker for mice but is secreted
by human Th1 and Th2 clones,37 and the production
of Th2-depedent IgG4 in non-atopics in the absence
of IgE.38 Since the subjects of the latter study were
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adult asthma patients including both atopic and non-
atopic types, heterogeneity of immune responses are
expected to be large. Asthmatic individuals with
dominant expression of IL-5 andor -9 compared with
IL-10 might have reduced UGRP1, and those with
dominant expression of IL-10 might have increased
UGRP1 in their lungs. It is likely that UGRP1 gene
expression may be under more complex regulation
and may be heterogeneous in human asthmatic air-
ways as compared to mice.
Finally, the effect of inhaled corticosteroid (ICS) in
asthma patients should be considered. A previous
mice study clearly demonstrated that systemic corti-
costeroids reversed the reduced expression of
UGRP1 in the airways.2 In this study, oral corticoster-
oid was found to increase plasma UGRP1 levels in se-
vere asthma patients. This may raise the possibility
that asthma patients treated with inhaled corticoster-
oid (ICS) might have reduced plasma UGRP1 levels.
In our study, 94.3% of asthma patients were treated
with ICS. Even in mild asthma patients, a major part
(77%) is treated with ICS. ICS might up-regulate the
expression of UGRP1 in their airways and increase
plasma UGRP1 levels in asthma patients, which
masks the difference between asthma patients and
controls.
In conclusion, UGRP1 levels in human plasma can
be determined with the newly established ELISA sys-
tem. Plasma UGRP1 levels are associated with the
G-112A UGRP1 promoter polymorphism and the se-
verity of asthma.
REFERENCES
1. Niimi T, Copeland NG, Gilbert DJ et al. Cloning, expres-
sion, and chromosomal localization of the mouse gene
(Scgb3a1, alias Ugrp2) that encodes a member of the
novel uteroglobin-related protein gene family. Cytogenet.
Genome. Res. 2002;97:120-127.
2. Niimi T, Keck-Waggoner CL, Popescu NC et al. UGRP1, a
uteroglobinClara cell secretory protein-related protein,
is a novel lung-enriched downstream target gene for the
TEBPNKX2.1 homeodomain transcription factor. Mol.
Endocrinol. 2001;15:2021-2036.
3. Bohinski RJ, Di Lauro R, Whitsett JA. The lung-specific
surfactant protein B gene promoter is a target for thyroid
transcription factor 1 and hepatocyte nuclear factor 3, in-
dicating common factors for organ-specific gene expres-
sion along the foregut axis. Mol. Cell Biol. 1994;14:5671-
5681.
4. Bruno MD, Bohinski RJ, Huelsman KM, Whitsett JA,
Korfhagen TR. Lung cell-specific expression of the
murine surfactant protein A (SP-A) gene is mediated by
interactions between the SP-A promoter and thyroid tran-
scription factor-1. J. Biol. Chem. 1995;270:6531-6536.
5. Kelly SE, Bachurski CJ, Burhans MS, Glasser SW. Tran-
scription of the lung-specific surfactant protein C gene is
mediated by thyroid transcription factor 1. J. Biol. Chem.
1996;271:6881-6888.
6. Ray MK, Chen CY, Schwartz RJ, DeMayo FJ. Transcrip-
tional regulation of a mouse Clara cell-specific protein
(mCC10) gene by the NKx transcription factor family
members thyroid transciption factor 1 and cardiac
muscle-specific homeobox protein(CSX). Mol. Cell Biol.
1996;16:2056-2064.
7. Kimura S, Hara Y, Pineau T et al. The Tebp null mouse:
thyroid-specific enhancer-binding protein is essential for
the organogenesis of the thyroid, lung, ventral forebrain,
and pituitary. Genes. Dev. 1996;10:60-69.
8. Reynolds SD, Reynolds PR, Pryhuber GS, Finder JD,
Stripp BR. Secretoglobins SCGB3A1 and SCGB3A2 de-
fine secretory cell subsets in mouse and human airways.
Am. J. Respir. Crit. Care Med. 2002;166:1498-1509.
9. Mukherjee AB, Chilton BS. The uteroglobinClara cell
protein family. Ann. NY. Acad. Sci. 2000;923:147-155.
10. Miele L, Cordella-Miele E, Facchiano A, Mukherjee AB.
Novel anti-inflammatory peptides from the region of high-
est similarity between uteroglobin and lipocortin I. Nature
1988;335:726-730.
11. Chiba Y, Srisodsai A, Supavilai P, Kimura S. Interleukin-5
reduces the expression of uteroglobin-related protein
(UGRP) 1 gene in allergic airway inflammation. Immunol.
Lett. 2005;97:123-129.
12. Chiba Y, Kusakabe T, Kimura S. Decreased expression of
uteroglobin- related protein 1 in inflamed mouse airways
is mediated by IL-9. Am. J. Physiol. Lung Cell. Mol. Physiol.
2004;287:L1193-1198.
13. Srisodsai A, Kurotani R, Chiba Y et al. Interleukin-10 in-
duces uteroglobin-related protein (UGRP) 1 gene expres-
sion in lung epithelial cells through homeodomain tran-
scription factor TEBPNKX2.1. J. Biol. Chem. 2004;279:
54358-54368.
14. Ober C, Moffatt MF. Contributing factors to the pathobi-
ology. The genetics of asthma. Clin. Chest Med. 2000;21:
245-261.
15. Postma DS, Bleecker ER, Amelung PJ et al. Genetic sus-
ceptibility to asthma―bronchial hyperresponsiveness co-
inherited with a major gene for atopy. N. Engl. J. Med.
1995;333:894-900.
16. Ruffilli A, Bonini S. Susceptibility genes for allergy and
asthma. Allergy 1997;52:256-273.
17. Bleecker ER. Mapping susceptibility genes for asthma
and allergy. Clin. Exp. Allergy 1998;28(Suppl 5):6-12; dis-
cussion 26-28.
18. Cookson WO, Moffatt MF. Genetics of asthma and aller-
gic disease. Hum. Mol. Genet. 2000;9:2359-2364.
19. Niimi T, Munakata M, Keck-Waggoner CL et al. A poly-
morphism in the human UGRP1 gene promoter that regu-
lates transcription is associated with an increased risk of
asthma. Am. J. Hum. Genet. 2002;70:718-725.
20. Asthma prevention and management guidelines. Ministry
of Health and Welfare, Japan. Int. Arch. Allergy Immunol.
2000;121(Suppl 1):I-VIII, 1-77.
21. Global Initiative for Asthma (GINA2002). Global Strategy
for Asthma Management and Prevention. National Institute
of Health, National Heart, Lung, and Blood Institute,
2002.
22. Jian Z, Nakayama J, Noguchi E, Shibasaki M, Arinami T.
No evidence for association between the -112GA poly-
morphism of UGRP1 and childhood atopic asthma. Clin.
Exp. Allergy 2003;33:902-904.
23. Chiba Y, Kurotani R, Kusakabe T et al. Uteroglobin-
related protein 1 expression suppresses allergic airway in-
flammation in mice. Am. J. Respir. Crit. Care Med. 2006;
173:958-964.
24. Hawrylowicz CM, O’Garra A. Potential role of interleukin-
10-secreting regulatory T cells in allergy and asthma. Nat.
Rev. Immunol. 2005;5:271-283.
Inoue K et al.
64 Allergology International Vol 57, No1, 2008 www.jsaweb.jp
25. Stampfli MR, Cwiartka M, Gajewska BU et al. Interleukin-
10 gene transfer to the airway regulates allergic mucosal
sensitization in mice. Am. J. Respir. Cell Mol. Biol. 1999;
21:586-596.
26. Oh JW, Seroogy CM, Meyer EH et al. CD4 T-helper cells
engineered to produce IL-10 prevent allergen-induced air-
way hyperreactivity and inflammation. J. Allergy Clin. Im-
munol. 2002;110:460-468.
27. Nicholson KG, Kent J, Ireland DC. Respiratory viruses
and exacerbations of asthma in adults. BMJ 1993;307:
982-986.
28. Johnston SL, Pattemore PK, Sanderson G et al. Commu-
nity study of role of viral infections in exacerbations of
asthma in 9-11 year old children. BMJ 1995;310:1225-
1229.
29. Busse WW, Gern JE. Is interleukin-10 a “10” in virus-
provoked asthma? Am. J. Respir. Crit. Care Med. 2005;
172:405-406.
30. Shijubo N, Itoh Y, Yamaguchi T et al. Clara cell protein-
positive epithelial cells are reduced in small airways of
asthmatics. Am. J. Respir. Crit. Care Med. 1999;160:930-
933.
31. Van Vyve T, Chanez P, Bernard A et al. Protein content in
bronchoalveolar lavage fluid of patients with asthma and
control subjects. J. Allergy. Clin. Immunol. 1995;95:60-68.
32. Shijubo N, Itoh Y, Yamaguchi T et al. Serum levels of
Clara cell 10-kDa protein are decreased in patients with
asthma. Lung 1999;177:45-52.
33. Renauld JC. New insights into the role of cytokines in
asthma. J. Clin. Pathol. 2001;54:577-589.
34. Holtzman MJ, Morton JD, Shornick LP et al. Immunity,
inflammation, and remodeling in the airway epithelial bar-
rier: epithelial-viral-allergic paradigm. Physiol. Rev. 2002;
82:19-46.
35. Umetsu DT. Revising the immunological theories of
asthma and allergy. Lancet 2005;365:98-100.
36. Heaton T, Rowe J, Turner S et al. An immunoepidemi-
ological approach to asthma: identification of in-vitro T-
cell response patterns associated with different wheezing
phenotypes in children. Lancet 2005;365:142-149.
37. Del Prete G, De Carli M, Almerigogna F et al. Human IL-
10 is produced by both type 1 helper (Th1) and type 2
helper (Th2) T cell clones and inhibits their antigen-
specific proliferation and cytokine production. J. Immu-
nol. 1993;150:353-360.
38. Platts-Mills T, Vaughan J, Squillace S, Woodfolk J, Sporik
R. Sensitisation, asthma, and a modified Th2 response in
children exposed to cat allergen: a population-based
cross-sectional study. Lancet 2001;357:752-756.
